Title: Quantification of Modifiable Risk Factors in Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma

Running head: Contribution of Modifiable Risk Factors in MGUS Progression

Author: Mei Wang, MS[1,2,3†]; Byron Sigel, MsC,[4†]; Lawrence Liu, MD[5]; John H. Huber, PhD[3]; Mengmeng Ji, PhD, MBBS[1,3]; Martin W. Schoen, MD, MPH[1,6]; Kristen M. Sanfilippo, MD, MPHS[1,4]; Theodore S. Thomas, MD, MPHS[1,4]; Graham A. Colditz, MD, DrPH[3], Shi-Yi Wang, MD, PhD[7]; Su-Hsin Chang, PhD, SM[1,3*]
1. Research Service, St. Louis Veterans Affairs Medical Center; St. Louis, MO
2. Division of Biology and Biomedical Sciences, Washington University School of Medicine; St. Louis, MO
3. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine; St. Louis, MO
4. Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO
5. City of Hope Comprehensive Cancer Center; Duarte, CA
6. Department of Medicine, Washington University School of Medicine; St. Louis, MO
7. Yale School of Public Health, Yale University; New Haven, CT
[†]Co-first authors.

*Corresponding Author: Su-Hsin Chang, PhD SM

Address: 660 S. Euclid Ave. Campus Box 8100, St. Louis, MO 63110

Email: chang.su-hsin@wustl.edu; Tel: (314) 362-8623

Funding: This work was supported by the Foundation for Barnes-Jewish Hospital; the Siteman Cancer Center; the National Institutes of Health Grants R01 CA253475 and U01 CA265735.

Abstract words: 153

Main text words: 3,957

Figures + Tables: 6

ABSTRACT

PURPOSE: Multiple myeloma (MM) is the most common plasma cell dyscrasia in the United States with notably significant health disparities. MM is preceded by an asymptomatic precursor monoclonal gammopathy of undetermined significance (MGUS). Studies have identified several risk factors for the progression of MGUS to MM; however, the relative contributions of these remain unknown. Particularly, understanding the contribution among those modifiable factors may inform MM prevention.

METHODS: This study quantified these contributions by estimating the adjusted population attributable fractions (aPAF) of modifiable risk factors for MM among the Veteran population with MGUS.

RESULTS: Among all evaluated risk factors, excess body mass index (BMI $\geq$25 kg/m²) was the leading factor (Black: aPAF=27.0%, 95% CI 19.3-33.9%; White: 27.1%, 95% CI 20.3-33.4%; All: aPAF=27.1%, 95% CI: 22.0-31.8%).

CONCLUSION: Our study highlights the potential for weight management as a key strategy in reducing the risk of progression to MM in Black and White patients diagnosed with MGUS.

INTRODUCTION

Multiple myeloma (MM) is the most prevalent plasma cell malignancy, accounting for ~10% of all hematologic cancers.[1,2] In 2024, it accounted for 35,780 new diagnoses and 12,540 deaths in the United States.[3] MM is preceded by monoclonal gammopathy of undetermined significance (MGUS), a pre-malignant condition that occurs in 3-10% of individuals aged ≥50 years and is twice as prevalent among individuals of African descent.[4-7] Notably, MGUS is linked to a 1% annual risk of progression to MM or other lymphoproliferative disorders.[5,8]

MM remains incurable, with a 5-year survival rate of only 61.1% from 2014-2020.[3] The management of MM also presents a significant financial burden.[9,10] Given the profound health and economic burden, there is a pressing need to elucidate key modifiable risk factors that contribute to the progression of MGUS to MM.[11,12] By quantifying the contribution of these risk factors, healthcare professionals and broader stakeholders, including policymakers and public health experts, can better risk stratify and develop targeted interventions to mitigate disease progression and reduce MM burden.

Prior studies have shown risk factors for MM, some of which are potentially modifiable, e.g., chemical exposure,[13-17] cumulative exposure to overweight/obesity,[18] and underlying comorbidities.[19-26] However, a comprehensive understanding of the extent to which these factors contribute to MM burden is lacking. Addressing this gap in knowledge is critical to inform efficient allocation of healthcare resources and refine follow-up care for MGUS patients.

MM prevention and control is further complicated by established MM health disparities. MM is more prevalent in Black individuals.[3] Previous studies have demonstrated that Black individuals progress from MGUS to MM at a younger age as compared to White individuals.[26-30] Disparities in the progression of MGUS to MM may be influenced by complex interaction

among biological, socio-contextual, and lifestyle factors.[31] Among these factors, the contribution

of modifiable risk factors to MM disparities remains unclear. Thus, a deeper understanding of the

role of each modifiable risk factor in the progression of MGUS to MM could offer valuable

insights for developing more targeted interventions to eliminate this racial disparity.

We aimed to conduct a population-based study to estimate the multivariable-adjusted

population attributable fraction (aPAF), both overall and stratified by race. By quantifying the

contribution of each modifiable risk factor, this approach provides a robust framework for

identifying key intervention targets to mitigate MM burden.

MATERIALS AND METHODS

Data and Study Population

Data from the nationwide U.S. Veterans Health Administration (VHA) were used. We selected

the Veteran population due to their distinct demographic characteristics, including older age, a

predominantly male composition, and higher prevalence of Agent Orange (AO) exposure, all of

which are associated with an increased risk of MM and progression of MGUS to MM. Therefore,

this group is at a heightened risk compared to the general population. Chemical exposure is a

crucial modifiable risk factor typically assessed through occupational history, which is often

poorly documented in most databases, including VHA. However, the VHA database provides

comprehensive records of AO exposure. AO, an herbicide used during the Vietnam War Era, is

contaminated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a highly toxic compound.

TCDD remains a prevalent occupational hazard, posing a considerable risk due to its prolonged

half-life of ~3.2 years.[32-36] Given the well-documented AO exposure in the VHA database, it

serves as a reliable proxy for chemical exposure.

The study was approved by Institutional Review Boards at both the Veteran Affair Saint

Louis Healthcare System and Washington University School of Medicine.

Analytic Cohort

We confirmed 50,096 Black or White patients diagnosed with MGUS from 10/1/1999 to

12/31/2023 with data available on immunoglobulin (Ig) subtype (Figure 1). MGUS and MM

diagnosis and the corresponding date of diagnosis were determined by validated natural language

processing (NLP) models.[37] Briefly, these models utilized clinical, laboratory, medication, and

pathologic data to extract evidence for MGUS and MM. This approach achieved an accuracy of

93% for MGUS and 99% MM,[37,38] as compared to only 20% and 58% for the approach using

billing codes alone.[37,39]

Self-reported race was ascertained from the Corporate Data Warehouse (CDW) and recoded as

Black or White based on published guidelines.[40] Patients with subtypes other than IgG, IgA, and

light chain were excluded, because IgM MGUS does not typically progress to MM and the others

are rare (n=9,084). Patients who progressed <6 months were also excluded because they may

have had MM at time of MGUS diagnosis (n=5,898). Finally, patients were excluded if their

documented date of death was on or before the same day of their MGUS diagnosis (n=41). The

final analytic cohort consisted of 35,073 patients, among whom 33.8% were Black.

Selected Modifiable Risk factors

Multiple CDW data domains in the VHA were linked to obtain patient-level data on risk factors

for progression of MGUS to MM selected based on previously published work,[6,11,26,41] clinical

judgement, and data availability. These risk factors included older age, male sex, Black race,

elevated body mass index (BMI), monoclonal (M-) spike level ≥1.5 g/dL, IgA subtype,

comorbidities (summarized by Charlson Comorbidity Index, CCI[42-44]), and chemical exposure

(measured by prior AO exposure).

Among these risk factors, BMI, chemical exposure, and CCI are potentially modifiable.

BMI was calculated based on the most frequently reported height and weight measurements ≤1

year prior to and closest to MGUS diagnosis. Excess BMI was further defined as BMI ≥25

kg/m^2.[41] Chemical exposure was determined by whether the patient met all of the following

criteria: exposure documented in CDW, AO location was designated as Vietnam, and ever

served in the Army, Air Force, Navy, or Marine Corps during the Vietnam War Era.[35] CCI was

calculated based on comorbidities present ≤1 year before MGUS diagnosis.[43,44]

Outcome Measure

The outcome variable was the progression of MGUS to MM, if any, and the time of MGUS to

MM. The diagnosis of MM and date of diagnosis were confirmed by the aforementioned

published NLP model.[37]

Statistical Analysis

Patient characteristics, stratified by progression, death without progression, and censoring, were

summarized as proportions for categorical variables and as medians (interquartile ranges, IQRs)

for continuous variables. Statistical significance for differences across groups was assessed using

chi-square tests for categorical variables and Kruskal-Wallis tests for continuous variables.

Competing risk analyses. Death prior to progression to MM was considered as a competing

event. For each of the studied modifiable risk factors, we plotted the cumulative incidence

function (CIF) curves, stratified by individual categories of that risk factor. Gray's test was

performed to compare the cumulative incidence of progression between categories.

Multivariable-adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for each

risk factor were estimated using Fine-Gray distribution hazard models.[45] Follow-up time was

defined as time from MGUS to progression, death, or the date of censoring (12/31/2023),

whichever occurred first. The independent variables in the multivariable models included: age,

gender (male, female), race (White, Black), Ig subtype (IgG, IgA, light-chain), M-spike level

($\leq$1.5, >1.5 g/dL), BMI (non-excess <25, excess $\geq$25 kg/m^2, missing), all at MGUS diagnosis,

and chemical exposure (yes, no), year of MGUS diagnosis, CCI (0, >0). Ig subtype was extracted

using a published NLP pipeline.[37]

aPAF analyses. For each modifiable risk factor significantly associated with the progression in

the multivariable analysis, aPAF was calculated. The aPAF quantifies the proportion of

progression events from MGUS to MM, at the population level, that may have been prevented if

the specific risk factor were not present in any of the MGUS patients. It requires both the

prevalence of each risk factor in the cohort and the adjusted relative risk for MM incidence

associated with this risk factor during follow-up. It also accounts for competing risk of death,

thereby reducing the possibility of overestimating aPAFs by ignoring censoring due to death.[46,47]

We estimated aPAFs for the following risk factor modifications: excess to non-excess BMI,

chemical exposure to no chemical exposure, and at least one comorbidity (CCI>0) to no

comorbidities (CCI=0).

Race-specific analyses. To determine whether racial differences exist in the contribution of

modifiable risk factors to progression from MGUS to MM, the analytic cohort was stratified by

race. The multivariable competing risk analysis and the aPAF analysis were repeated without

including race as an independent variable. Differences in aPAFs between the two racial groups

were analyzed using two-sample z-tests.

Sensitivity analyses. We performed the same analyses but replacing the excess BMI with BMI

classification: underweight <18, normal weight 18-<25, overweight 25-<30, obese ≥30, and

missing. We calculated the aPAF for the following modifications: overweight to normal weight,

obese to normal weight, chemical exposure to no chemical exposure, and no comorbidities to at

least one comorbidity.

All tests were two-sided. Statistical significance was assessed at the level of 0.05. Data

queries were performed using SQL Server Management Studio 18 (Microsoft, Redmond, WA).

All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).

RESULTS

The analytic cohort included 35,073 patients with MGUS, of whom 2,895 (8.3%) progressed to

MM, and 15,541 (44.3%) died without progression. The median follow-up was 3.8 (IQR: 1.5-7.3)

years. The median age of MGUS diagnosis was 71.8 (IQR: 64.4-78.6) years (Table 1). The

cohort was predominantly male (96.0%) and White 66.2%. More than half of the MGUS patients

had excess BMI (73.1%). Compared to Veterans who died without progression or were censored,

Veterans who progressed to MM were diagnosed with MGUS at a younger age (median: 67.6

(progression) versus 75.0 (died) versus 69.9 (censored) years, p<0.0001), had shorter follow-up

time (median: 2.3 versus 3.7 versus 4.3 years, p<0.0001), were more likely to be Black (39.1%

versus 29.3% versus 37.0%, p<0.0001), had abnormal M-spike level at study entry (22.1%

versus 7.7% versus 3.8%, p<0.0001), and had IgA subtype (17.7% versus 11.9% versus 11.5%,

p<0.0001).

Patients across racial groups were statistically significantly different in all variables

(Supplementary Table 1).

Competing risk analyses

Statistically significant differences were observed in the cumulative incidence of progression

across categories of each modifiable risk factor (Figure 2A-C). Notably, the CIF curves

demonstrated that the cumulative incidence of progression was higher for patients who had

excess BMI compared to non-excess BMI (p<0.0001, Figure 2A). Veterans with chemical

exposure had higher cumulative incidence compared to those without chemical exposure

(p<0.0001, Figure 2B). Veterans with comorbidities showed a significantly increased cumulative

incidence compared to those with no comorbidities (p=0.0009, Figure 2C).

Multivariable analyses demonstrated that all included modifiable factors were

significantly associated with the progression of MGUS to MM (Table 2). Excess BMI

(aHR=1.24, 95% CI=1.13-1.35), chemical exposure (aHR=1.30, 95% CI=1.16-1.46), and

comorbidities (aHR=1.33, 95% CI=1.20-1.49) were independently associated with an elevated

risk of MGUS progression.

aPAF analyses

Excess BMI was estimated to be responsible for 27.1% (95% CI=22.0-31.8%) of MM cases in

the VHA (Figure 3A). Additionally, had all patients never been exposed to AO, the MM burden

may have been 3.9% (95% CI=2.5-5.2%) lower. If all patients had no comorbidities, the MM

burden may have been 7.8% higher, although this result was not statistically significant (95%

CI=-16.5-0.2%). If all patients had ≥1comorbidity (reverse comorbidity from CCI=0 to >0), the

MM burden may have been 0.9% lower (95% CI=-0.8-2.6%). See Supplementary Table 2 for all

risk factors for the progression of MGUS to MM. If the age of MGUS diagnosis decreased by

one-year, an estimated 5.1% (95% CI=4.8-5.4%) of MM cases could be attributed to this change.

Male gender accounted for 14.6% (95% CI=-2.7-29.0%) of MM cases. Black race accounted for

5.3% (95% CI=2.6-8.0%) of MM cases. IgA accounted for 5.1% (95% CI=3.8-6.4%) of MM

cases.

Race-specific analyses

Excess BMI was associated with an elevated risk of MGUS progression in both White patients

(aHR=1.20, 95% CI=1.07-1.35) and Black patients (aHR=1.29, 95% CI=1.12-1.49) (Table 2).

Having comorbidities was associated with a higher risk of MGUS progression in both groups

(aHR$_{White}$=1.36, 95% CI=1.19-1.56; aHR$_{Black}$=1.28, 95% CI=1.07-1.53). Additionally, MGUS

patients with chemical exposure were more likely to progress to MM among White patients

(aHR$_{White}$=1.38, 95% CI=1.20-1.58); however, among Black patients, this finding did not reach

statistical significance (aHR$_{Black}$ =1.11, 95% CI=0.91-1.36).

In race-specific aPAF analyses, there was no statistically significant difference in aPAFs

by race for excess BMI (aPAF$_{White}$=27.1%, 95% CI=20.3-33.4%; aPAF$_{Black}$=27.0%, 95%

CI=19.3-33.9%; p-difference=0.9764, Supplementary Table 2). As shown in Figure 4A, excess

BMI emerged as the top modifiable risk factor across both racial groups. The contribution of

chemical exposure was greater for White patients (aPAF$_{White}$=5.6%, 95% CI=3.6-7.6%;

aPAF$_{Black}$=1.8%, 95% CI=0.2-3.4%; p-difference=0.0036). Additionally, changing CCI from at

least one comorbidity to no comorbidities was estimated to result in an increase of 9.2% of MM

cases among White patients (95% CI=-20.5-1.1%) and 4.9% among Black patients (95% CI=-

18.7-7.3%), although the difference is not statistically significant (p-difference=0.6085). See

Supplementary Table 2 for race-specific aPAFs for non-modifiable risk factors.

Sensitivity Analyses

Consistent with the main analysis for excess BMI, obesity and overweight remained the top two

modifiable risk factors (Figure 3B, $aPAF_{obesity}$=13.2%, 95% CI=9.8-16.4%; $aPAF_{overweight}$=10.1%,

95% CI=7.3-12.7%).

The burden of MM cases attributable to obesity was higher for White patients

($aPAF_{White}$=14.3%, 95% CI=9.8-18.5%) as compared to Black patients ($aPAF_{Black}$=11.9%, 95%

CI=6.7-16.7%) (Figure 4B). The proportion of MM cases attributable to overweight was lower

for White patients than Black patients ($aPAF_{White}$=9.7%, 95% CI=6.1-13.2%; $aPAF_{Black}$=10.7%,

95% CI=6.6-14.7%).

DISCUSSION

To the best of our knowledge, this is the first study to quantify the burden of MGUS progression

attributable to each identified risk factor. Notably, in this large national cohort of Veterans, we

identified excess BMI as the most significant contributor to the progression of MGUS to MM

among all evaluated risk factors, accounting for 27.1% of the MGUS cases that progressed to

MM. Furthermore, excess BMI was the leading contributor to the progression of MGUS to MM

in both racial groups: White 27.1%; Black 27.0%.

Our study highlights the crucial role of obesity in MGUS progression. These findings

align with prior research indicating that obesity promotes the progression of MGUS to MM

through several biological mechanisms.[7,19,48-50] Previous studies have demonstrated that obesity

is associated with elevated levels of inflammatory cytokines, including tumor necrosis factor

alpha, C-reactive protein, and interleukin-6. Elevated levels of these markers support the survival

and proliferation of MM cells within the bone marrow.[48,51,52] Furthermore, studies have

demonstrated that weight loss results in a significant reduction in plasma levels of pro-

inflammatory cytokines.[53-55] Additionally, obesity disrupts the balance in the production and

secretion of adipokines, such as increased leptin and decreased adiponectin, both of which can

influence cellular processes that further the progression to MM.[56,57] Together, these factors

underscore the complex interplay between metabolic and inflammatory processes in the

progression of MGUS to MM. Therefore, considering that excess BMI contributes most to the

overall risk among selected risk factors but is also modifiable, weight management emerges as a

potentially impactful prevention strategy to mitigate the progression of MGUS to MM.

Comorbidities, including type-2 diabetes mellitus and other obesity-related diseases, e.g.,

hypertension, heart diseases, was associated with an increased risk of progression from MGUS to

MM, as shown by the CIF and multivariable analysis. However, the aPAF showed a non-

statistically significant association for modifying ≥1 comorbidity to no comorbidities. When

estimating the aPAFs for progression, the relative risks of progression and death were both taken

into account. Higher CCI is strongly associated with both the progression and all-cause mortality.

In analyses where CCI was modified from >0 to 0, the reduction in the death events may have

outweighed the reduction in the progression events, potentially leading to an increase in the

progression cases. The relationship between comorbidities and MGUS progression may be

influenced by a combination of complex underlying factors, e.g., metabolic dysregulation and

inflammatory pathways. These factors are also closely intertwined with the effects of obesity.

Thus, our study suggests the need to further explore the role of concurrent conditions in MGUS

progression.

In addition, our study uniquely contributes to the existing evidence by quantifying

exposure to chemical herbicide. We estimated that chemical exposure was responsible for 3.9%

of MM cases. Previous studies have demonstrated that chemical exposure is a risk factor for

MGUS and its progression, possibly due to contamination with TCDD.[32-36] Importantly, TCDD

is a common contaminant in various occupational pesticides. While longitudinal occupational

pesticide exposure is difficult to track and not captured in most datasets, the VHA data provide a

unique opportunity to study the impact of chemical exposure via the exposure of AO. This

provides insights into the long-term effects of environmental and occupational chemical

exposures, informing policies for exposure prevention and management. Similar studies have

found that occupational pesticide exposure is associated with a higher risk of MGUS and MM.[13-

17] Therefore, our findings underscore the importance of considering environmental exposures in

developing targeted prevention strategies, particularly for MGUS patients with a high risk (or

even a history) of occupational or environmental TCDD exposure.

We found that younger age at MGUS diagnosis was associated with higher risk of

progression of MGUS to MM. This finding aligns with previous retrospective studies using

secondary data on the relationship between age and MGUS progression.[35,58] Similar to

comorbidities, this negative association may be explained by competing risk of death as older

age is strongly associated with a higher risk of all-cause mortality. Hence, if an individual has a

shorter lifespan after MGUS diagnosis,[8] they may not have had sufficient time for MGUS to

progress to MM, resulting in a negative association with age. This is further supported by the

observation that patients in our dataset diagnosed with MGUS at an older age ($\geq$ median age of

71.8 years) had a shorter average follow-up duration of 3.9 years, compared to 6.1 years for

those diagnosed at a younger age (<71.8 years). This difference may be attributed to higher

mortality rates in the older population (54.4%) versus the younger cohort (34.2%). Therefore, it

is crucial to investigate whether differences in follow-up time or other underlying effects of

comorbidities in older patients may influence the progression of MGUS to multiple myeloma.

Previous research has provided strong evidence on increased risk of MGUS and MM

among Black compared to White populations.[26,28,30] However, our race-specific analyses

demonstrate that the aPAFs of selected modifiable risk factors are larger in White compared to

Black individuals. These racial and ethnic disparities may be attributed to socio-contextual

factors, potentially linked to underlying health inequities.[59,60] Excess BMI emerged as a

prominent modifiable risk factor for MGUS progression in both racial groups. Without excess

BMI, progression to MM may have been prevented in 27.1% of White patients and 27.0% of

Black patients. Additionally, the aPAF for obesity is higher in White individuals than in Black

individuals. However, the aPAF for overweight is higher in Black individuals than in White

individuals. Although these differences were not statistically significant, addressing excess BMI

as a modifiable risk factor could substantially reduce the MM burden, in both racial groups.

Furthermore, we evaluated chemical exposure and CCI by racial group, recognizing that

genetic, environmental, and socio-economic factors may differentially impact MGUS

progression. The contribution of chemical exposure was more pronounced in White individuals

than in Black individuals. However, there was no statistically significant racial difference in the

contribution of modifying no comorbidities to at least one comorbidity. In our cohort, the

prevalence of chemical exposure was slightly higher in White individuals than in Black

individuals. Furthermore, the multivariable competing-event analyses showed that the impact of

chemical exposure was greater in White individuals compared to Black individuals. These

findings warrant further studies on the racial differences in the impact of chemical exposure on

MGUS progression and provide a foundation for developing equitable, population-specific

prevention and intervention strategies tailored to address disparities in environmental and

occupational chemical exposure.

Nevertheless, in addition to modifiable risk factors included in our analyses, other

factors, such as family history/genetics, could play a role in the observed racial differences in

MM progression.[60] Therefore, further research is warranted to elucidate the underlying

mechanisms and implications of these findings and to explore potential contributing factors.

Ultimately, these results suggest the need to develop tailored interventions for specific

subpopulations.[6,30,60,61]

Our study has several strengths. First, we used a large national cohort of Veterans with

NLP-confirmed MGUS/MM diagnoses. The NLP model greatly improved diagnosis accuracy

from 20% to 93% for MGUS and from 58% to 99% for MM, compared to using administrative

billing codes alone.[37-39] Second, we leveraged the unique characteristics of the Veterans

population, notably their documented exposure to chemical, to investigate the association of

chemical exposure on MGUS progression at the population level. The detailed CDW data

allowed a more precise assessment of this risk factor, which is typically hard to capture in other

databases. Third, we conducted a race-specific analysis of aPAFs to explore potential racial

differences in the contribution of modifiable risk factors to MGUS progression. Identifying

which racial group has a higher burden of MGUS progression is crucial when planning

prevention strategies aiming for reducing health disparities. As racial disparities in MM are long-

established, by examining the contribution of modifiable risk factors to MGUS progression

separately for White and Black populations, the study provides insight into any differential

contribution of these factors on MM development, potentially identifying interventions to reduce

MM health disparities. Fourth, the application of a comprehensive aPAF method that accounts

for the competing risk of death addresses a crucial limitation frequently encountered in studies

examining disease progression; specifically, MGUS/MM predominantly affect older adults who

face a higher risk of dying from causes unrelated to the disease of interest before progressing to

the disease outcome. This enhances the validity of our findings by minimizing the possibility of

overestimating aPAF.

296   Our study has limitations. First, our study lacks risk factors, e.g., family history,[11,61,62]

smoking status,[11,63] and dietary intake,[64] as these are not recorded simply as structured data in the

VHA. Administrative or EHR databases primarily capture medical and healthcare utilization

information, making it challenging to gather detailed information on family history and lifestyle

factors. The VHA data combined administrative and EHR data, which could provide us further

information on family history and lifestyle factors. As such, further data abstraction or

development of NLP algorithms will be needed to retrieve the data. Second, the generalizability

of our findings to other populations is limited because the Veteran population is predominantly

male. However, the insights gained from the Veteran population can inform future investigation

in more diverse cohorts. Third, the retrospective and observational nature does not allow for the

establishment of causal relationships between risk factors and MGUS progression. Future

prospective studies are warranted to establish a causal link between these risk factors and MGUS

progression. Fourth, despite using a validated NLP model to confirm MGUS and MM diagnoses,

misclassification cannot be completely ruled out. However, we do not anticipate that the

misclassification is high as our study shows that the NLP model achieved 93% accuracy for

MGUS confirmation and 99% for MM. Last, the interpretation of aPAFs should be approached

with caution. Rather than predicting the practical impact of reversing these risk factors, they

should be considered as an indication of their contribution to the progression of MGUS to MM.

The reality of implementing interventions to modify these risk factors may be complex and may

require further investigation. Nonetheless, recognizing these limitations, our study offers

important insights into the relative contributions of key risk factors in the progression of MGUS

to MM in the Veterans population.

CONCLUSION

In conclusion, our study quantifies the relative contribution of modifiable risk factors to the

progression of MGUS to MM among Veterans. Among the variables studied, our results indicate

that excess BMI is the top contributor to the burden of MGUS progression. As one of the few

modifiable risk factors currently identified, these results underscore the potential impact of

targeted interventions, such as lifestyle modifications and weight management, on reducing

MGUS progression. Moreover, excess BMI emerged as the leading contributor for the

progression of MGUS in both Black and White patients. Further research is needed to validate

these findings across different populations and to identify additional risk factors to inform MM

prevention.

REFERENCES

1.   Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol*. Aug 2022;97(8):1086-1107. doi:10.1002/ajh.26590

2.   Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. Nov 2014;15(12):e538-48. doi:10.1016/S1470-2045(14)70442-5

3.   SEER. National Cancer Institute: Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Myeloma. Accessed July 8, 2024. https://seer.cancer.gov/statfacts/html/mulmy.html

4.   El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. *Lancet Haematol*. May 2022;9(5):e340-e349. doi:10.1016/S2352-3026(22)00069-2

5.   Kyle RA, Larson DR, Therneau TM, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. *N Engl J Med*. Jan 18 2018;378(3):241-249. doi:10.1056/NEJMoa1709974

6.   Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. *Blood*. Feb 1 2006;107(3):904-6. doi:10.1182/blood-2005-08-3449

7.   Landgren O, Rajkumar SV, Pfeiffer RM, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. *Blood*. Aug 19 2010;116(7):1056-9. doi:10.1182/blood-2010-01-262394

8.   Ji M, Huber JH, Schoen MW, et al. Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance. *JAMA Oncol*. Sep 1 2023;9(9):1293-1295. doi:10.1001/jamaoncol.2023.2278

9.   Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma. *Expert Rev Hematol*. Jun 2022;15(6):473-475. doi:10.1080/17474086.2022.2081147

10.   de Oliveira C, Pataky R, Bremner KE, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. *BMC Cancer*. Oct 18 2016;16(1):809. doi:10.1186/s12885-016-2835-7

11.   Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. *Ann Hematol*. Apr 2021;100(4):855-863. doi:10.1007/s00277-021-04400-7

12.   Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. *Blood*. Jun 6 2019;133(23):2484-2494. doi:10.1182/blood.2019846782

13.   Baris D, Silverman DT, Brown LM, et al. Occupation, pesticide exposure and risk of multiple myeloma. *Scand J Work Environ Health*. Jun 2004;30(3):215-22. doi:10.5271/sjweh.782

14.   Brown LM, Burmeister LF, Everett GD, Blair A. Pesticide exposures and multiple myeloma in Iowa men. *Cancer Causes Control*. Mar 1993;4(2):153-6. doi:10.1007/BF00053156

15.   Khuder SA, Mutgi AB. Meta-analyses of multiple myeloma and farming. *Am J Ind Med*. Nov 1997;32(5):510-6. doi:10.1002/(sici)1097-0274(199711)32:5<510::aid-ajim11>3.0.co;2-5

16.   Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. *Blood*. Jun 18 2009;113(25):6386-91. doi:10.1182/blood-2009-02-203471

17.   Packard E, Shahid Z, Groff A, Patel R, Jain R. Multiple Myeloma in an Agricultural Worker Exposed to Pesticides. *Cureus*. May 28 2019;11(5):e4762. doi:10.7759/cureus.4762

18.   Liu L, Grandhi N, Wang M, et al. Cumulative Excess Body Mass Index and MGUS Progression to Myeloma. *JAMA Netw Open*. 2024;(e2458585)doi:10.1001/jamanetworkopen.2024.58585 (In production)

19.   Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. *Int J Cancer*. 2007;120 Suppl 12:40-61. doi:10.1002/ijc.22718

20.   Birmann BM, Giovannucci EL, Rosner BA, Colditz GA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study. *Cancer Prev Res (Phila)*. Jan 2014;7(1):33-41. doi:10.1158/1940-6207.CAPR-13-0224

21.   Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. Jun 2010;24(6):1121-7. doi:10.1038/leu.2010.60

22.   Pasqualetti P, Collacciani A, Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. *Am J Hematol*. Jul 1996;52(3):217-20. doi:10.1002/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C

23.   Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. *Blood*. Oct 1 2007;110(7):2586-92. doi:10.1182/blood-2007-05-088443

24.   Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood*. Aug 1 2005;106(3):812-7. doi:10.1182/blood-2005-03-1038

25.   Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. *Mayo Clin Proc*. Oct 2010;85(10):933-42. doi:10.4065/mcp.2010.0337

26.   Chang SH, Luo S, Thomas TS, et al. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. *J Natl Cancer Inst*. May 2017;109(5)doi:10.1093/jnci/djw264

27.   Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. *Leukemia*. Jul 2014;28(7):1537-42. doi:10.1038/leu.2014.34

28.   Huber JH, Ji M, Shih YH, Wang M, Colditz G, Chang SH. Disentangling age, gender, and racial/ethnic disparities in multiple myeloma burden: a modeling study. *Nat Commun*. Sep 20 2023;14(1):5768. doi:10.1038/s41467-023-41223-8

29.   Ji M, Shih YH, Huber JH, et al. Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study. *Cancer Epidemiol Biomarkers Prev*. Aug 6 2024;doi:10.1158/1055-9965.EPI-24-0490

30.   Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. *Blood*. Dec 16 2010;116(25):5501-6. doi:10.1182/blood-2010-07-298760

31.   Waters EA, Colditz GA, Davis KL. Essentialism and Exclusion: Racism in Cancer Risk Prediction Models. *J Natl Cancer Inst*. Nov 29 2021;113(12):1620-1624. doi:10.1093/jnci/djab074

32.   Bumma N, Nagasaka M, Hemingway G, et al. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. *Clin Lymphoma Myeloma Leuk*. May 2020;20(5):305-311. doi:10.1016/j.clml.2019.11.014

33.   Kort J, O'Brien T. FISH abnormalities in Agent Orange–associated multiple myeloma. *Journal of Clinical Oncology*. 2023;41(16_suppl):e20056-e20056. doi:10.1200/JCO.2023.41.16_suppl.e20056

34.   Landgren O, Shim YK, Michalek J, et al. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study. *JAMA Oncol*. Nov 2015;1(8):1061-8. doi:10.1001/jamaoncol.2015.2938

35.   Liu LW, Wang M, Grandhi N, et al. The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans. *J Hematol Oncol*. Jan 8 2024;17(1):3. doi:10.1186/s13045-023-01521-6

36.   Wang L, Kumar M, Deng Q, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. *Cancer Lett*. Jan 2019;440-441:135-144. doi:10.1016/j.canlet.2018.10.009

37.   Wang M, Yu YC, Liu L, et al. Natural Language Processing-Assisted Classification Models to Confirm Monoclonal Gammopathy of Undetermined Significance and Progression in Veterans' Electronic Health Records. *JCO Clin Cancer Inform*. Sep 2023;7:e2300081. doi:10.1200/cci.23.00081

38.   La J, DuMontier C, Hassan H, et al. Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. *Pharmacoepidemiol Drug Saf*. May 2023;32(5):558-566. doi:10.1002/pds.5579

39.   Wang M, Yu Y-C, Liu L, et al. Natural language processing of Veterans' electronic health records to confirm diagnoses of monoclonal gammopathy of undetermined significance. *Journal of Clinical Oncology*. 2022;40(16_suppl):1557-1557. doi:10.1200/JCO.2022.40.16_suppl.1557

40.   Document VOHDQPDQG. Best Practices Guide – Race Data. Accessed July 8, 2024. http://vaww.vhadataquality.va.gov/index.php?option=com_phocadownload&view=category&id=18&Itemid=4 74&lang=en

41.   Liu L, Grandhi N, Wang M, et al. Cumulative Excess Body Mass Index and MGUS Progression to Myeloma. *JAMA Netw Open*. Feb 3 2025;8(2):e2458585. doi:10.1001/jamanetworkopen.2024.58585

42.   Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8

43.   Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol*. Jun 1992;45(6):613-9. doi:10.1016/0895-4356(92)90133-8

44.   Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. *J Clin Epidemiol*. Oct 1993;46(10):1075-9; discussion 1081-90. doi:10.1016/0895-4356(93)90103-8

45.   Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. Jun 1999;94(446):496-509. doi:Doi 10.2307/2670170

46.   Laaksonen MA, Harkanen T, Knekt P, Virtala E, Oja H. Estimation of population attributable fraction (PAF) for disease occurrence in a cohort study design. *Stat Med*. Mar 30 2010;29(7-8):860-74. doi:10.1002/sim.3792

47.   Laaksonen MA, Virtala E, Knekt P, Oja H, Härkänen T. SAS Macros for Calculation of Population Attributable Fraction in a Cohort Study Design. *J Stat Softw*. Jul 2011;43(7):1-25.

48.   Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. *Curr Opin Support Palliat Care*. Dec 2009;3(4):263-8. doi:10.1097/SPC.0b013e3283311d09

49.   Cammisotto PG, Bendayan M. Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. *J Mol Histol*. Dec 2008;39(6):579-84. doi:10.1007/s10735-008-9198-6

50.   Thordardottir M, Lindqvist EK, Lund SH, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. *Blood Adv*. Nov 14 2017;1(24):2186-2192. doi:10.1182/bloodadvances.2017007609

51.   Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nat Rev Cancer*. Aug 2007;7(8):585-98. doi:10.1038/nrc2189

52.   Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: A Chronic Low-Grade Inflammation and Its Markers. *Cureus*. Feb 2022;14(2):e22711. doi:10.7759/cureus.22711

53.   Bianchi VE. Weight loss is a critical factor to reduce inflammation. *Clin Nutr ESPEN*. Dec 2018;28:21-35. doi:10.1016/j.clnesp.2018.08.007

54.   Phillips CL, Grayson BE. The immune remodel: Weight loss-mediated inflammatory changes to obesity. *Exp Biol Med (Maywood)*. Jan 2020;245(2):109-121. doi:10.1177/1535370219900185

55.   Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. *Circulation*. Feb 19 2002;105(7):804-9. doi:10.1161/hc0702.104279

56.   Tie W, Ma T, Yi Z, et al. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines. *Pathol Oncol Res*. 2023;29:1611338. doi:10.3389/pore.2023.1611338

57.   Zorena K, Jachimowicz-Duda O, Slezak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. *Int J Mol Sci*. May 18 2020;21(10)doi:10.3390/ijms21103570

58.   Chang SH, Gumbel J, Luo S, et al. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. *Cancer Epidemiol Biomarkers Prev*. Dec 2019;28(12):2055-2061. doi:10.1158/1055-9965.EPI-19-0132

59.   Bunce CM, Drayson MT. Dissecting racial disparities in multiple myeloma-clues from differential immunoglobulin levels. *Blood Cancer J*. Apr 28 2020;10(4):44. doi:10.1038/s41408-020-0314-5

60.   Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. *Blood Cancer J*. Feb 17 2020;10(2):19. doi:10.1038/s41408-020-0284-7

61.   Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. *Blood*. Jun 7 2012;119(23):5359-66. doi:10.1182/blood-2011-11-387324

62.   Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. *Blood*. Jul 23 2009;114(4):791-5. doi:10.1182/blood-2008-12-191676

63.   Boursi B, Weiss BM, Haynes K, Mamtani R, Yang YX. Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. *Am J Hematol*. Jun 2016;91(6):581-4. doi:10.1002/ajh.24355

64.   Joseph JM, Hillengass J, Tang L, et al. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. *Blood Adv*. Feb 13 2024;8(3):538-548. doi:10.1182/bloodadvances.2023011608

Table 1. Characteristics by progression status in Veterans diagnosed with MGUS in the VHA from 10/1/1999 to 12/31/2023.

	Total	Progression	Death	Censored	p-value*
N	35,073	2,895	15,541	16,637	
%	100.0%	8.3%	44.3%	47.4%	
Gender (%)					<0.0001
Female	4.0	3.1	1.9	6.2	
Male	96.0	96.9	98.1	93.8	
Race (%)					<0.0001
Black	33.8	39.1	29.3	37.0	
White	66.2	60.9	70.8	63.0	
Excess BMI (%)					<0.0001
Non-excess BMI	26.0	21.4	32.0	21.1	
Excess BMI	73.1	78.2	67.0	78.0	
Missing	0.9	0.5	1.0	0.9	
BMI (%)					<0.0001
Underweight	1.9	0.8	2.8	1.1	
Normal weight	24.1	20.6	29.2	20.0	
Overweight	35.5	36.7	35.2	35.7	
Obese	37.6	41.5	31.8	42.3	
Missing	0.9	0.5	1.0	0.9	
M-spike (%)					<0.0001
≤1.5 g/dL	61.1	47.4	59.0	65.5	
>1.5 g/dL	7.1	22.1	7.7	3.8	
Missing	31.8	30.4	33.3	30.6	
MGUS type (%)					<0.0001
IgA	12.2	17.7	11.9	11.5	
IgG	71.1	71.1	70.4	71.8	
Light-chain	16.7	11.2	17.6	16.7	
Chemical exposure (%)					<0.0001
No	89.9	88.2	93.0	87.2	
Yes	10.1	11.8	7.0	12.8	
CCI↑ (%)					<0.0001
0	15.6	13.5	10.2	20.9	
>0	84.5	86.5	89.8	79.1	
Follow-up (years)					<0.0001
Median	3.8	2.3	3.7	4.3	
IQR	1.5-7.3	1.1-4.9	1.5-7.0	1.7-8.0	
Age					<0.0001
Median	71.8	67.6	75.0	69.9	
IQR	64.4-78.6	60.9-74.2	67.4-82.0	62.6-75.7	
Calendar year of MGUS diagnosis					<0.0001

	Median	2016	2012	2012	2019
	IQR	2010-2020	2007-2017	2007-2017	2015-2022

MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; aHR, adjusted hazard ratio; aPAF, adjusted population attributable fraction; CI, confidence interval; Ig, immunoglobulin; CCI, Charlson comorbidity index; IQR, interquartile range.

* Chi-square tests were conducted to compare percentages for categorical variables and Kruskal–Wallis tests were used to compare medians for continuous variables between the three groups.

↑ CCI was calculated based on data collected within 1 year before MGUS diagnosis.

Table 2. Overall and race-specific multivariable-adjusted hazard ratios for the progression of MGUS to MM.

Risk factors	All		White		Black	
	aHR (95% CI)*	p-value	aHR (95% CI)*	p-value	aHR (95% CI)*	p-value
Age	0.971 (0.968-0.975)	<.0001	0.967 (0.963-0.971)	<.0001	0.978 (0.973-0.983)	<.000
Gender						
Female	1.00 (referent)		1.00 (referent)		1.00 (referent)	
Male	1.48 (1.19-1.83)	0.0004	1.63 (1.17-2.26)	0.0038	1.35 (1.01-1.80)	0.042
M-spike$^{\uparrow}$						
≤1.5 g/dL	1.00 (referent)		-		-	
>1.5 g/dL	1.12 (1.04-1.21)	0.0048	-	-	-	
Race						
White	1.00 (referent)		1.00 (referent)		1.00 (referent)	
Black	4.37 (3.96-4.82)	<.0001	4.58 (4.04-5.20)	<.0001	4.12 (3.53-4.80)	<.000
Ig subtype$^{\uparrow}$						
IgG	1.00 (referent)		1.00 (referent)		1.00 (referent)	
IgA	1.55 (1.41-1.71)	<.0001	1.68 (1.49-1.90)	<.0001	1.38 (1.17-1.62)	<.000
Light-chain	0.76 (0.67-0.86)	<.0001	0.74 (0.63-0.86)	<.0001	0.79 (0.64-0.99)	0.040
BMI$^{\uparrow}$						
Non-excess BMI	1.00 (referent)		1.00 (referent)		1.00 (referent)	
Excess BMI	1.24 (1.13-1.35)	<.0001	1.20 (1.07-1.35)	0.0022	1.29 (1.12-1.49)	0.000
Chemical exposure						
No	1.00 (referent)		1.00 (referent)		1.00 (referent)	
Yes	1.30 (1.16-1.46)	<.0001	1.38 (1.20-1.58)	<.0001	1.11 (0.91-1.36)	0.314
CCI						
0	1.00 (referent)		1.00 (referent)		1.00 (referent)	
>0	1.33 (1.20-1.49)	<.0001	1.36 (1.19-1.56)	<.0001	1.28 (1.07-1.53)	0.005
Year of MGUS diagnosis	0.97 (0.97-0.98)	<.0001	0.97 (0.96-0.98)	<.0001	0.98 (0.97-0.99)	0.000

MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; aHR, adjusted hazard ratio; CI, confidence interval; Ig, immunoglobulin; CCI, Charlson comorbidity index.
*HRs were additionally adjusted for M-spike level at MGUS (≤1.5 g/dL, >1.5 g/dL, missing), and year of MGUS diagnosis.
$\uparrow$ Missing M-spike, and missing BMI categories are not presented.

Figure 1. Flowchart of patient selection

Figure 2. Cumulative incidence of progression to MM among 35,073 MGUS patients for each modifiable risk factor.

(A) Main analysis

(B) Sensitivity analysis

Main analysis: BMI categorized into: excess BMI ≥25, non-excess BMI <25, and missing; Sensitivity analysis: BMI categorized into: underweight <18, normal weight 18-<25, overweight 25-<30, obese ≥30, and missing.
aPAF, adjusted population attributable fraction; CI, confidence interval.
†Hypothetical exposure modifications from risk factor exposure level to target reference level.
‡In the main analysis, aPAF for modifying no comorbidity to at least one comorbidity was 0.9 (95% CI: -0.8-2.6);
  in the sensitivity analysis, aPAF for modifying no comorbidity to at least one comorbidity was 0.8 (95% CI: -0.9-2.5).

Figure 3. Multivariable-adjusted population attributable fractions for selected modifiable risk factors of the progression of MGUS to MM

(A) Main analysis

(B) Sensitivity analysis

Main analysis: BMI categorized into: excess BMI ≥25, non-excess BMI <25, and missing; Sensitivity analysis: BMI categorized into: underweight <18, normal weight 18-<25, overweight 25-<30, obese ≥30, and missing.

aPAF, adjusted population attributable fraction; CI, confidence interval.

†Hypothetical exposure modifications from risk factor exposure level to target reference level.

‡In the main analysis, aPAF for modifying no comorbidity to at least one comorbidity was 1.5 (95% CI: -0.9-3.8) for White and 0.2 (95% CI: -2.5-2.8) for Black; in the sensitivity analysis, aPAF for modifying no comorbidity to at least one comorbidity was 1.4 (95% CI: -1.0-3.7) for White and 0.1 (95% CI: -2.5-2.7) for Black.

Figure 4. Race-specific multivariable-adjusted population attributable fractions for selected modifiable risk factors of the progression of MGUS to MM.

Supplementary Table 1. Characteristics by race in Veterans diagnosed with MGUS in the VHA from 10/1/1999 to 12/31/2023.

	White	Black	P-value*
N	23,234	11,839	
%	66.2%	33.8%	
Outcome (%)			<0.0001
Confirmed progression	7.6	9.6	
Death without progression	47.3	38.4	
Censoring	45.1	52.0	
Gender (%)			<0.0001
Female	3.1	5.9	
Male	96.9	94.1	
Excess BMI (%)			<0.0001
Non-excess BMI	24.8	28.3	
Excess BMI	74.2	71.0	
Missing	1.0	0.7	
BMI (%)			<0.0001
Underweight	1.5	2.6	
Normal weight	23.3	25.6	
Overweight	36.7	33.4	
Obese	37.5	37.7	
Missing	1.0	0.7	
M-spike (%)			<0.0001
≤1.5 g/dL	59.9	63.6	
>1.5 g/dL	6.7	7.7	
Missing	33.4	28.6	
MGUS type (%)			<0.0001
IgA	11.6	13.4	
IgG	69.8	73.8	
Light-chain	18.7	12.8	
Chemical exposure (%)			<0.0001
No	89.0	91.6	
Yes	11.0	8.4	
CCI↑ (%)			<0.0001
0	94.4	95.3	
>0	5.6	4.7	
Age (years)			<0.0001
Median	73.3	68.4	
IQR	66.3-79.8	61.0-75.6	
Follow-up (years)			<0.0001
Median	3.7	4.0	

IQR	1.5-7.2	1.6-7.6	
Calendar year of MGUS diagnosis			0.0384
Median	2016	2016	
IQR	2010-2020	2011-2020	

MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; aHR, adjusted hazard ratio; aPAF, adjusted population attributable fraction; CI, confidence interval; Ig, immunoglobulin; CCI, Charlson comorbidity index; IQR, interquartile range.

* Chi-square tests were conducted to compare percentages for categorical variables and Kruskal–Wallis tests were used to compare medians for continuous variables between the three groups.

↑ CCI was calculated based on data collected within 1 year before MGUS diagnosis.

Supplementary Table 2. Multivariable-adjusted population attributable fractions for selected risk factors of the progression of MGUS to MM.

Risk factors	Modifications†	aPAF, % (95% CI)*			
		Overall	**White**	**Black**	**p-difference****
Age					
	Increase by 1 year	5.1 (4.8-5.4)	5.7 (5.4-6.1)	4.3 (3.9-4.7)	<0.0001
Gender					
Female	Male to Female	14.6 (-2.7-29.0)	24.3 (-1.6-43.6)	3.7 (-20.8-23.3)	0.1924
Male					
Race					
White	Black to White	5.3 (2.6-8.0)	-	-	-
Black					
Ig subtype↑					
IgG	IgA to IgG	5.1 (3.8-6.4)	5.8 (4.1-7.5)	4.1 (2.0-6.2)	0.2289
	Light-chain to IgG	-5.9 (-7.4--4.4)	-6.7 (-8.8--4.8)	-4.9 (-6.7--3.0)	0.1547
IgA					
Light-chain					
Excess BMI status↑					
Non-excess BMI	Excess BMI to non-excess BMI	27.08 (22.0-31.8)	27.14 (20.3-33.4)	27.00 (19.3-33.9)	0.9764
Excess BMI					
CCI					
	>0 to 0 (i.e., at least one comorbidity to no comorbidities)	-7.3 (-16.0-0.7)	-9.2 (-20.5-1.1)	-4.9 (-18.7-7.3)	0.6085
Chemical exposure					
No	Chemical exposure to No chemical exposure	3.9 (2.5-5.2)	5.6 (3.6-7.6)	1.8 (0.2-3.4)	0.0036
Yes					

MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; aHR, adjusted hazard ratio; aPAF, adjusted population attributable fraction; CI, confidence interval; Ig, immunoglobulin; CCI, Charlson comorbidity index.

†Hypothetical exposure modifications from risk factor exposure level to target reference level.

*HRs and aPAFs were additionally adjusted for M-spike level at MGUS (≤1.5 g/dL, >1.5 g/dL, missing), and year of MGUS diagnosis.

**p-differences were based on two-sample z-tests in comparing differences in aPAFs between White and Black.

↑Missing BMI category is not presented.